Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Systems Biological Assessment of the Durability of Vaccine Responses
NCT05801978Phase 4Recruiting
- Sponsor
- Emory University
- Start
- Apr 2023
- Primary completion
- Sep 2027
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 4, open-label trial of 17D yellow fever vaccine in yellow fever and influenza (2 arms), sponsored by Emory University. Primary endpoints: Magnitude of neutralizing antibody response against YF-17D in blood up to 270 days and Magnitude of neutralizing antibody response against QIV in blood up to 270 days. Started Apr 2023; status: recruiting.
02
Drugs
17D yellow fever vaccine
03
Conditions
yellow feverinfluenza
Beyond the preview
Go deeper on NCT05801978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05801978.